Joyce Sutcliffe is the Chief Executive Officer of Synbactis Inc., a newly formed company interested in host-directed therapies to prevent antibiotic-induced nephrotoxicity.
She has more than 35 years’ experience in antibiotic research and development and has previously been an independent consultant and the former Senior Vice President (SVP) of Tetraphase Pharmaceuticals where she was responsible for managing discovery biology and preclinical development internally and with external contractors.
As part of the executive team, she was involved in developing clinical strategies, marketing, budgeting resourcing, regulatory submissions, government contracts and, managing awarded contracts.
Before joining Tetraphase, Joyce was VP of Research at the NanoBio Corporation where she led antimicrobial, antiviral and antifungal discovery activities. She was Chief Research Scientist at Rib-X Pharmaceuticals for six years and spent 20 years at Pfizer and Abbott where she played key roles in early-stage antibiotic discovery and development through to phase II activities.
Joyce is part of the Scientific Advisory Board for the TB alliance, the Institute for Life Science Entrepreneurship, and the Small World Initiative and has authored 65 papers as well as one book and is a named inventor on 20 patents. She has participated in the discovery and development of various antibiotics including azithromycin, delafloxacin, radezolid, and eravacycline.
Joyce received her PhD in microbiology from the University of Florida, which she followed with a postdoctoral position at the University of Massachusetts Medical School and a staff fellowship at the National Institutes of Health.